博济医药科技股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》和《深圳证券交易所创业板上市公 司自律监管指南第 2 号——公告格式》等有关规定，博济医药科技股份有限公司 （原名"广州博济医药生物技术股份有限公司"，以下简称"公司"或"博济医 药"）董事会编制了截至 2025 年 6 月 30 日募集资金存放与实际使用情况的专项 报告。 一、 募集资金基本情况 （一）实际募集金额及资金到位情况 经中国证券监督管理委员会《关于同意广州博济医药生物技术股份有限公司 向特定对象发行股票注册的批复》（证监许可〔2020〕3230 号）同意注册，公 司向特定对象发行 A 股股票 33,450,584 股，发行价格 10.26 元/股，募集资金总 额 34,320.30 万元，扣除各项发行费用（不含增值税）678.63 万元，公司实际募 集资金净额为 33,641.67 万元。上述募集资金已于 2021 年 6 月 18 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-068 博济医药科技股份有限公司 关于计提资产减值损失、信用减值损失及核销资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次计提资产减值损失、信用减值损失情况概述 （一）本次计提资产减值损失、信用减值损失的原因 博济医药科技股份有限公司（以下简称"公司"）本次计提资产减值准备， 是依照《企业会计准则》及公司会计政策的相关规定进行的。公司及下属子公司 对 2025 年半年度末各类存货、应收款项、合同资产、固定资产、在建工程、无 形资产、商誉、持有待售资产等资产进行了全面清查，对各类存货的可变现净值、 应收款项及合同资产回收的可能性、固定资产、在建工程、无形资产及持有待售 资产的可变现性进行了充分的评估和分析，认为上述资产中部分资产存在一定的 减值迹象，本着谨慎性原则，公司需对可能发生资产减值损失的相关资产进行计 提减值准备。 （二）本次计提资产减值损失的资产范围和总金额 公司及下属子公司对 2025 年半年度末存在可能发生减值迹象的资产（范围 包括合同资产、存货）进行全面清查和资产 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-070 博济医药科技股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《博济医药科技股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，经博济医药科技股份有限公司（以下简称"公司"或"本公司"）第 五届董事会第十六次会议审议通过，决议于 2025 年 9 月 12 日以现场投票与网 络投票相结合的方式召开公司 2025 年第一次临时股东大会，现将本次股东大会 有关事项通知如下： 一、 本次股东大会召开的基本情况 1、股东大会届次：2025 年第一次临时股东大会。 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次会议的召开已经公司第五届董事会第十 六次会议审议通过，召集程序符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 4、会议召开时间： （1）现场会议召开时间：2025 年 9 月 12 日（星期五）下午 14:30。 （2）网络投票时间：2025 年 9 月 12 日。其中，通过深圳 ...

博济医药科技股份有限公司 第五届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届监事会第十五次会 议于 2025 年 8 月 25 日在公司会议室召开，会议采取现场投票方式对议案进行表 决。本次会议通知于 2025 年 8 月 15 日以专人送达、电子邮件、电话、微信等方 式发出。会议应到监事 3 人，实到 3 人。会议由监事会主席刘菁纯女士主持。本 次监事会的召集、召开符合《公司法》《公司章程》及相关法规的规定。 二、 监事会会议审议情况 1、 审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 证券代码：300404 证券简称：博济医药 公告编号：2025-066 表决结果：同意 3 票；反对 0 票；弃权 0 票。 3、 审议通过了《关于作废部分限制性股票的议案》 经审核，监事会一致认为：公司《2025 年半年度报告》及《2025 年半年度 报告摘要》的内容真实、准确、完整的反映了公司 2025 年半年度经营的实际情 况，不存在任何虚假记载、 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-065 本议案已经公司董事会审计委员会审议通过。 博济医药科技股份有限公司 第五届董事会第十六次会议决议公告 二、董事会会议审议情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、 审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 经审议，董事会一致认为：公司《2025 年半年度报告》及《2025 年半年度 报告摘要》符合法律法规、中国证监会和深圳证券交易所的相关规定，报告内容 真实、准确，完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 8 月 25 日在公司会议室召开，会议采取现场结合通讯投票的方式对 议案进行表决。本次会议通知于 2025 年 8 月 15 日以专人送达、电子邮件、电话、 微信等方式发出。会议应到董事 7 人，实到 7 人，会议由董事长王廷春先生主持， 部分监事和部分高管列席了本次董事会。本次董事会的召集、召开符合《公司法》 《公司章程》及相关法 ...

Business Strategy and Development - The company plans to leverage its unique "one-stop" service advantage to adjust its business structure and development direction in response to potential stricter NMPA drug approval requirements[3]. - The company aims to enhance its core competitiveness through strategic planning and layout, utilizing its full industry chain service advantages amid increasing competition in the domestic CRO market[6]. - The company is expanding its business into preclinical research services and CDMO services, facing potential risks due to competition and lack of experience in these new areas[8]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with the expansion of its operational scale and business scope[8]. - The company is committed to strengthening internal training and talent reserves to enhance its ability to withstand risks in the evolving regulatory environment[3]. - The company plans to enhance its risk management strategies in response to potential policy changes affecting new drug approvals and research investments[90]. - The company aims to expand its business into innovative drug clinical services and preclinical services to mitigate risks associated with market competition[91]. Financial Performance - The company's operating revenue for the reporting period reached RMB 361,448,457, representing a 5.88% increase compared to RMB 341,390,828.56 in the same period last year[25]. - The net profit attributable to shareholders decreased by 48.33% to RMB 15,569,864.27 from RMB 30,135,149.57 year-on-year[25]. - The net cash flow from operating activities significantly increased by 343.46%, amounting to RMB 21,245,267.43 compared to RMB 4,790,796.04 in the previous year[25]. - Total assets at the end of the reporting period were RMB 1,563,950,571.44, a 7.81% increase from RMB 1,450,592,225.50 at the end of the previous year[25]. - The company reported a basic earnings per share of RMB 0.0407, down 48.42% from RMB 0.0789 in the previous year[25]. - The company achieved total operating revenue of CNY 361,448,457, representing a year-on-year growth of 5.88%[39]. - Net profit attributable to shareholders decreased by 48.33% to CNY 15,569,864, while the net profit excluding non-recurring gains and losses fell by 53.28% to CNY 11,988,298[39]. Market Trends and Industry Insights - The global CRO market size grew from USD 59.2 billion to USD 92.7 billion over the past five years, with a projected CAGR of 9.93%[33]. - The Chinese CRO market is expected to reach RMB 118.3 billion in 2024, with a CAGR of approximately 20%[33]. - The clinical CRO market in China is projected to grow from RMB 26.3 billion in 2020 to RMB 83.5 billion by 2025, with a CAGR of 25.99%[33]. - The number of clinical trial applications accepted by the National Medical Products Administration increased from 1,830 in 2021 to 2,818 in 2024[34]. Operational Challenges and Risk Management - The company acknowledges the risks of contract execution delays in new drug development due to various factors, including clinical research failures and changes in client research directions[4]. - The company has established specific responsibility models in contracts to address potential delays and will conduct careful evaluations of project execution difficulties before accepting new projects[5]. - The company recognizes the need for improved budget management due to the long execution cycles of some innovative drug development contracts[4]. - The company will maintain good communication with clients to minimize the risks of cost overruns and insufficient profits during contract execution[5]. Research and Development - The company has filed for 8 invention patents, enhancing its core competitiveness through independent intellectual property rights[44]. - The company is advancing several innovative drug projects, including a new drug for chronic heart failure and a new drug for high uric acid levels, with significant progress reported[44]. - The company has established a comprehensive "one-stop" service capability for new drug development, significantly reducing time, research, communication, and conversion costs for clients[48]. Subsidiaries and Investments - The company has established a new subsidiary, Xinxin Traditional Chinese Medicine Technology, with no significant impact on overall operations and performance[89]. - The company has invested significantly in preclinical research capabilities, establishing a one-stop service platform with advanced technical features and advantages[51]. - The company has completed 100% of its promised investment in the R&D project as of the reporting date[78]. Corporate Governance and Compliance - The company emphasizes corporate governance and shareholder rights, ensuring compliance with relevant laws and regulations[107]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[111]. - There were no violations regarding external guarantees during the reporting period[112]. Shareholder Information and Stock Options - The company completed the third exercise period of the 2022 stock option incentive plan, with 1.1564 million stock options available for 60 incentive targets at an exercise price of 8.73 CNY per share[99]. - A total of 22.264 million stock options were canceled due to unexercised options from the second exercise period of the 2022 stock option incentive plan[100]. - The first vesting conditions of the 2023 restricted stock incentive plan were achieved, with 607,800 shares available for 39 incentive targets, and 458,400 shares were actually vested and listed for trading[101]. Related Party Transactions - The company engaged in related party transactions, including providing clinical research services valued at 21.42 million yuan, accounting for 0.52% of similar transaction amounts[118]. - Another related party transaction involved providing clinical research services valued at 290.57 million yuan, accounting for 1.00% of similar transaction amounts[118]. Future Outlook - The company plans to expand its market presence, focusing on new product development and technological advancements[190]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its portfolio[190].

Core Insights - Boji Pharmaceutical (300404) closed at 11.76 yuan on August 25, 2025, with a 3.43% increase and a turnover rate of 16.99% [1] - The company reported a total revenue of 139 million yuan for Q1 2025, a year-on-year decrease of 17.06%, and a net profit attributable to shareholders of 3.90 million yuan, down 76.38% year-on-year [1] Financial Performance - Total revenue for Q1 2025: 139 million yuan, down 17.06% year-on-year [1] - Net profit for Q1 2025: 3.90 million yuan, down 76.38% year-on-year [1] - Non-recurring net profit: 1.70 million yuan, down 88.28% year-on-year [1] - Current ratio: 1.935, Quick ratio: 1.418, Debt-to-asset ratio: 31.99% [1] Market Activity - Main capital inflow: 18.48 million yuan, accounting for 3.32% of transaction volume [1] - Large orders net inflow: 19.49 million yuan, accounting for 3.5% of transaction volume [1] - Small orders net outflow: 23.88 million yuan, accounting for 4.29% of transaction volume [1] Company Background - Boji Pharmaceutical was established in 2002 and is located in Guangzhou, focusing on research and experimental development [2] - The company has invested in 39 enterprises and participated in 113 bidding projects [2] - Intellectual property includes 49 trademarks and 47 patents, along with 44 administrative licenses [2]

Group 1 - The fifth Shenzhen Biopharmaceutical Innovation Conference was held, focusing on innovation and international development in the biopharmaceutical industry, aiming to promote high-quality integration and global cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area [1] - The conference attracted nearly 3,500 participants, including around 200 industry experts and representatives, with over 3,300 attending via online streaming [1] - The global pharmaceutical industry is undergoing significant changes, with advancements in AI technology shortening drug development cycles and accelerating the internationalization of Chinese pharmaceutical companies [1] Group 2 - The founder of Yaoduo, Li Jing, highlighted that the export of Chinese innovative drugs has become a norm, with the License-out transaction amount expected to exceed 400 billion yuan in 2024, and the first payment nearing 36 billion yuan [2] - Emerging fields such as ADC, bispecific antibodies, and cell therapy are becoming highlights for Chinese companies going global, with a shift from "engineering manufacturing" to "original innovation" [2] - The global pharmaceutical market is projected to reach 19 trillion yuan by 2027, with oncology, autoimmune, and metabolic fields remaining key growth drivers [2] Group 3 - A roundtable discussion focused on the implementation of the Class B medical insurance catalog, emphasizing the importance of drug economic evaluation, real-world data sharing, and a one-stop settlement mechanism for innovative drugs to benefit Chinese patients [3] - The biopharmaceutical industry in China is transitioning from "local innovation" to "global value," requiring technological innovation, capital support, policy backing, and international cooperation to gain a more significant position in the global pharmaceutical landscape [3] - The conference provided insights and practical strategies for the industry, facilitating efficient platforms for collaboration between enterprises and capital, as well as domestic and international partnerships [3]

Core Insights - The fifth Shenzhen Biopharmaceutical Innovation Conference was successfully held, focusing on innovation and international development in the biopharmaceutical industry, aiming to promote high-quality integration and global cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area [1] Group 1: Conference Overview - The conference adopted a dual-mode format of offline main venue and online live streaming, attracting nearly 3,500 participants, including industry experts, corporate representatives, and investors [1] - Keynote speeches and discussions centered around "new opportunities for biopharmaceutical innovation and going global," with significant participation from various stakeholders in the industry [1][2] Group 2: Key Themes and Discussions - The conference theme was "Leading Innovation Change, Insight into Transformation Pathways," focusing on the commercialization of innovative drugs and the dual circulation of internal and external markets [2] - The global pharmaceutical market is projected to reach $19 trillion by 2027, with oncology, autoimmune, and metabolic fields being the main growth drivers [2][3] - Challenges for companies going global include geopolitical issues, registration barriers, and commercialization difficulties, necessitating capabilities in market insight, efficient registration, channel coverage, academic support, and risk management [3] Group 3: Collaborative Efforts and Future Directions - The conference emphasized the need for collaboration among industry, academia, research, medicine, and investment sectors to build a globally competitive biopharmaceutical innovation ecosystem [2] - The discussions highlighted that the Chinese biopharmaceutical industry is at a critical stage of transitioning from "local innovation" to "global value," requiring technological innovation, capital support, policy backing, and international cooperation [3]

证券代码：300404 证券简称：博济医药 公告编号：2025-063 博济医药科技股份有限公司 关于募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （一） 募集资金的管理情况 为了规范募集资金的管理和使用，保护投资者权益，公司依照《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律、法规的规定，结合公司的实际情况，制 定了《募集资金管理制度》，对募集资金的存储、使用、用途变更及监督管理作 出了明确规定。 博济医药科技股份有限公司（以下简称"公司"或"博济医药"）2021 年向 特定对象发行股票的募集资金按照相关法律、法规和规范性文件的规定在银行开 立了募集资金专项账户。近日，公司办理完成了募集资金专项账户的注销手续， 现将具体情况公告如下： 二、募集资金存放和管理情况 本公司对募集资金实行专户存储，并对募集资金的使用执行严格的审批程序， 以保证专款专用。 1 2021 年，公司、全资子公司广州华圣制药有限公司（以下简称"华圣制药"， 原名"广州博济生物医药科技 ...